Skip to content

Role of solidarity between TB patient and DOT provider in treatment outcome

Community Volunteers, Solidarity and Case Management of Tuberculosis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/08/007203
Enrollment
4000
Registered
2016-08-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- DOT provider performance for TB patients

Interventions

Intervention1: Community DOT provider from patients sub caste: Patients randomly assigned to this arm will be asked to list five people from their sub caste from which one community DOTS provider will

Sponsors

National Institute of Child Health and Human Development NICHD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Pulmonary TB patients- Category I and II who are eligible to receive treatment from Study TU PHC

Exclusion criteria

Exclusion criteria: Age less than 18years, Extra pulmonary TB, MDR and XDR TB

Design outcomes

Primary

MeasureTime frame
For smear positive TB patients, treatment success will be measured by 1) treatment completion of the RNTCP standard anti-TB regimen for all patients 2) smear conversion at second month, cure at the completion of treatment for smear positive patients (as measured by control program)Timepoint: 2nd month- smear conversion 6th month/8th month- treatment completion and cure 6 months after completion- maintanence of smear negative status

Secondary

MeasureTime frame
From patient, information on social support received and stigma experienced after TB diagnosis, relationship with DOTS provider etc. From DOTS provider, information on solidarity and social support that DOT providers share with patient, pre-existing social ties to the patient, obstacles to the treatment process etcTimepoint: Intake form- after consent Initial form- 2 weeks after intensive phase- 2 months after treatment - 6 months and six months after completion of treatment

Countries

India

Contacts

Public ContactDr Shantidani Minz

Christian Medical College Vellore

minzshanti@gmail.com04162284207

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026